A Study of Higher Single Doses of MK0941 in Type 2 Diabetics

Trial Profile

A Study of Higher Single Doses of MK0941 in Type 2 Diabetics

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs MK 0941 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 05 Jan 2012 Actual end date changed from Mar 2010 to Jan 2010 as reported by ClinicalTrials.gov.
    • 03 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top